Positron Opens State-of-the-Art Training Center
September 13 2010 - 7:30AM
Positron Corporation (OTCBB:POSC), a molecular imaging company
specializing in Nuclear Cardiology and a leader in Cardiac PET,
announced today the grand opening of its Clinical and Technical
Cardiovascular PET Training Institute in Niagara Falls, NY.
The training center will educate physicians, technologists,
nurses and administrators on the use and benefits of cardiac PET
imaging in the daily operations of their facility. The
training will be done in a partnership with the Heart Center of
Niagara where Positron's medical director, Michael E. Merhige,
M.D., F.A.C.C currently operates a Coronary Artery Disease Reversal
and Prevention Center guided by Positron PET imaging
technologies.
Positron's chief technical officer, Joe Oliverio, stated, "This
center will be a critical tool in building awareness of the
tangible benefits a dedicated cardiac PET scanner yields.
Creating a center specifically geared towards disseminating
information is critically important as we work to grow the
adaptation of PET scanners into the medical imaging
marketplace. As an early adaptor of cardiac PET imaging, Dr.
Merhige is an ideal ambassador to the medical community; tapping
into the combined decades of experience Dr. Merhige and Positron's
clinical staff possess, will allow a seamless transition of users
from SPECT to PET."
Dr. Michael E. Merhige said, "Cardiac PET has been around since
1995, but only until very recently has the necessary peer-reviewed
literature been available to allow for its proper
recognition. PET scanning for cardiac use exposes the patient
to significantly reduced levels of radiation, compared to SPECT,
while affording physicians a highly effective diagnostic tool.
I am pleased to play a role in educating my peers on the
benefits of a cardiac PET scanner."
About Positron: Positron is a molecular
imaging company focused on Nuclear Cardiology. Positron utilizes
its proprietary product line to provide unique solutions to the
Nuclear Medicine community ranging from imaging to
radiopharmaceutical distribution. Positron products include:
the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging
device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical
distribution device; and the Tech-Assist™, a radiopharmaceutical
injection shield. More information about Positron is
available at www.positron.com.
Forward Looking Statements: Statements in
this document contain certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and estimates and are not
guarantees of future performance and may involve known and unknown
risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Positron Corporation to be
materially different from future results, performance or
achievements expressed or implied by such forward-looking
statements. Positron assumes no obligation to publicly update
or revise these forward-looking statements for any reason, or to
update the reasons actual results could differ materially from
those anticipated in these forward-looking statements, even if new
information becomes available in the future. Our actual
results may differ materially from the results anticipated in these
forward-looking statements due to a variety of factors, including,
without limitation those set forth as "Risk Factors" in our filings
with the Securities and Exchange Commission.
CONTACT: Positron Corporation
(317)576-0183.
Positron (PK) (USOTC:POSC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Positron (PK) (USOTC:POSC)
Historical Stock Chart
From Apr 2023 to Apr 2024